Another view point rescued from the swamp Sunspotter

New Post Public Reply Private Reply Replies (1) Message Board
farrell Chemdeps #69965
735
Another view point rescued from the swamp

Sunspotter (MAKO 2.0)

Minnie's comments refer to your highlighting in the article you posted...the substance of your commentary..."Does brilacidin cause phospholipidosis?

YOUR POSTS CLEARLY ADDRESSES, STATES and IS CENTERED UPON THAT "NON-ISSUE" but raising it as a serious issue:

Quote:"This is a very interesting article, that tells us at least one possible reason why some drugs that work very well in vitro then fail in vivo:

https://www.sciencenews.org/article/coronavir...ment-drugs

"That finding could help researchers avoid dead-ends. If a drug stops the coronavirus from growing in cells in the lab, researchers should test for phospholipidosis. If the drug causes that side effect, it should be discarded as a COVID-19 therapy."

Does brilacidin cause phospholipidosis?"



(BUT...THEN WE GO ON TO PLAY "LET'S ASSUME"...!)

Quote:"If (and I emphasize that I am not claiming this is definitively the case) Brilacidin's antiviral in vitro activity is related to phospholipidosis, then the clinical study is likely to fail."



Yes, the post is not "claiming this is definitively (so) "...but one would have to conclude that the post is "strongly suggesting"...AND IS stating Non-Definitively..."Brilacidin may be causing phospholipidosis"

BUT THERE IS ONLY ONE PROBLEM, AS POINTED OUT IN PJ's POST below points out...DURING THE JUST-COMPLETED BRILACIDIN/COVID-19 CLINICAL TRIAL:

...A "Safety Review" by the Independent Monitoring Committee was conducted on the first 25% of the participants who received 3 days of Brilacidin Dosing...THERE WAS NO DETECTION OF "phospholipidosis!

...Some poster is saying..."prove the negative"...Well, there was no evidence of phospholipidosis...IF THERE WAS EVIDENCE, the Clinical Trial would have been stopped right there!

CATEGORICALLY CORRECT!!!...a RED HERRING was thrown out at unsuspecting investors who might not "KNOW WHAT THEY OWN!"

There is and was no basis for questioning ... since a thorough Safety Review was already done on by an INDEPENDENT (SAFETY) MONITORING COMMITTEE...AND THE CLINICAL TRIAL WAS NOT STOPPED AND NO SAFETY ISSUES, INCLUDING phospholipidosis!


Quote J007 Thursday, 07/29/21 03:51:40 PM
Re: None 0
Post #
367896
of 367988
The Safety Review by the Independent Monitoring Committee...after the 3-day dosage regimen for 30 days... the Safety Review by this independent monitoring committee...did not recommend ending the trial for “futility.” as the other trials in the article noted...safety review...IMO they would have picked up on "a potentially serious side effect called phospholipidosis."

......Some poster is saying...prove the negative...Well, there was no evidence of phospholipidosis...otherwise, the Clinical Trial would have been stopped right there!



A follow-up post...states:

Quote:sunspotter Member Level Thursday, 07/29/21 04:10:59 PM
Re: PJ007 post# 367896
Post #
367901
of 367904
Quote:
"IMO they would have picked up on "a potentially serious side effect called phospholipidosis."

Please please read the article and my original post.

I'm not saying that brilacidin causes phospholipidosis in humans.

It's to do with the in vitro MoA against coronaviruses.





...there is only one problem in the above assertion... CONTENT OF FIRST POST IS ALL ABOUT BRILACIDIN/PHOSPHOLIPIDOSIS...the post essentially has nothing to do with "in vitro MoA against coronaviruses"...


Asserting:
"I'm not saying that brilacidin causes phospholipidosis in humans."

no...but the post did imply:

...there is "non-definitive evidence" ... when all along... if there was evidence of PHOSPHOLIPIDOSIS... is caused by Brilacidin...

IT IS IN DIRECT CONTRADICTION ... to the fact that ...

THERE WAS NO DETECTION or EVIDENCE OF "phospholipidosis by the"Safety Review" by the Independent Monitoring Committee after conducting the SAFETY REVIEW OF BRILACIND on the first 25% of the participants who received 3 days of Brilacidin Dosing!

Who to believe? ...an Independent Monitoring Committee reviewing SAFETY, or a Poster

NOT DIFFICULT... "KNOW WHAT YOUR OWN"!

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aurra Markets Wins 'Most Transparent Broker' Award 2026

Updated Category News Views 1

Spotlight on Transparency in Trading Alright, so Aurra Markets snagged the 'Most Transparent Broker' award at the Money Expo in Mumbai this year. From the greasy streets of trading floors to the polished halls of Jio World Convention Centre, transparency is one of those golden words you hear tossed around, but like finding a needle in a haystack, it’s not always easy to...

Continue Reading
LITEON Bets Big on Liquid Cooling with DCX Stake

Updated Category News Views 2

Liquid Cooling: The AI Data Center Game Changer Alright, here's a twist in the tech saga that even a crusty old trader like me finds intriguing. LITEON (2301.TW) has made a bold move investing in DCX Liquid Cooling Systems with a $176 million deal for 25% equity. We're talking about liquid cooling here—it's the magic ingredient when your AI and HPC data centers start...

Continue Reading
Ares Management Heads to Barclays Conference Spotlight

Updated Category News Views 4

All Eyes on Ares – From the Trading Floor to Barclays Nothing like the crisp snap of traders' attention when big players like Ares Management Corporation (NYSE:ARES) are set to spill some beans at a fancy conference. Come September 16, 2026, Ares' head honcho, Michael Arougheti, will be hitting the stage at the Barclays Global Financial Services Conference. It’s the...

Continue Reading
Curaleaf Eyes Growth: Conference Signals Opportunities

Updated Category News Views 0

Curaleaf's Strategic Move: Getting in Front of Investors Here comes Curaleaf Holdings, stepping into the spotlight with their eye on increasing investor engagement. Announcing their participation in the ATB Cormark Capital Markets 2026 Fall Institutional Investor Conference, the folks at Curaleaf aren't just talking—they're putting their top brass under the lights. You...

Continue Reading
Navimow's H5 Pro Mower Marries Tech with Nature Care

Updated Category News Views 2

Garden Tech Reinvented: Enter the H5 Pro Mower Welcome to the 21st-century garden, where robotic ingenuity meets a genuine regard for nature. Folks, the Navimow H5 Pro just rolled onto the scene and it’s tearing up the old playbook of garden maintenance. It’s like blending Silicon Valley tech with Jane Goodall’s wildlife sensibilities. We're talking zero-edge...

Continue Reading
Joseph Spine Opens New Regenerative Therapy Center

Updated Category News Views 1

Regenerative Medicine: A New Frontier in Spine Care When spine care gets a facelift, you take notice. Joseph Spine Institute, a heavyweight in the spine care game, just threw hat into the regenerative ring. We're talking about using a patient's own cells to mend what's broken—that's advanced. They're launching a Regenerative Therapy Center in Tampa, ready to offer these...

Continue Reading
Eosera Defies Odds with Texas-Made Ear Care Dominance

Updated Category News Views 1

Who would've thought an ear care outfit outta Fort Worth could snag a spot on the Inc. 5000 list for six years running? That's right, eosera® is hanging tough, even while the industry's been in a tailspin and tariffs have been squeezing everyone’s margins. Pushing Through Tough Terrain The ear care sector isn't exactly the first place investors look for a splash,...

Continue Reading
Perspecta's Study Reveals Troubling Data Accuracy Gaps

Updated Category News Views 1

Data Accuracy in Healthcare: A Persistent Problem Just when you think data's about numbers and cold, hard facts, healthcare jolts you awake. Perspecta's fresh insights onto provider data accuracy aren't just a snooze fest of statistics but a genuine wake-up call. This report peels open a can of worms some might prefer to ignore. With only half of provider data accurate,...

Continue Reading
Nasdaq Flashes Warning Signs for Scage Future's Compliance

Updated Category News Views 2

Two Strikes from Nasdaq: A Wake-Up Call? Scage Future's getting a double-shot of reality from Nasdaq after slipping under crucial thresholds. Here's the score: Scage's been dinged on their Market Value of Listed Securities (MVLS) and Market Value of Publicly Held Shares (MVPHS). Over a stretch from mid-July to late August, these benchmarks floundered below the line. The...

Continue Reading
Alcatraz AI: A Silent Titan in Data Center Security

Updated Category News Views 0

Why Alcatraz AI is the Security of Choice Forget flashy press releases and splashy marketing campaigns. Alcatraz AI, a company operating out of the hustle and bustle of Cupertino, has managed to quietly dominate a key sector without many folks being the wiser. What's their claim to fame, you ask? They're the chosen gatekeepers for over half of the hyperscale data centers...

Continue Reading

Top 5 Most Recently Viewed Articles

QuinStreet Achieves Unprecedented Fiscal Growth

Updated Category News Views 46

QuinStreet Reports Exceptional Financial Performance QuinStreet, Inc. (NASDAQ: QNST), recognized for its innovative performance marketing solutions, recently unveiled astounding financial results, showcasing a robust increase that has positioned the company as a leader in its sector. Record Revenue Growth For the recent fiscal quarter, QuinStreet reported an impressive...

Continue Reading
Senti Bio to Showcase Innovative Gene Therapies at SEED 2025

Updated Category News Views 185

Senti Bio to Showcase Innovative Gene Therapies at SEED 2025 Senti Biosciences, Inc. (Nasdaq: SNTI), a pioneering clinical-stage biotechnology company, is set to present at the highly anticipated 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference. This premier event, taking place from June 23 to June 26, 2025, is an essential gathering for...

Continue Reading
Monthly Distributions Announced by Premium Income Corporation

Updated Category News Views 135

Premium Income Corporation Monthly Distribution Details Premium Income Corporation has declared an update regarding its monthly distributions which will be beneficial for its shareholders. This announcement highlights the allocation of payments to different share classes, ensuring that investors are well-informed about their upcoming earnings. Distribution Schedule The...

Continue Reading
Why Branded Condominiums in Miami Are a Smart Investment Option

Updated Category News Views 235

Branded Condominiums: A Growing Trend in Miami In the competitive world of real estate, luxury developers are increasingly tapping into the appeal of branded condominiums to attract high-net-worth clients. These upscale residential projects are no longer just about prime locations; they incorporate well-known retail and lifestyle brands to appeal to discerning buyers....

Continue Reading
Investors Anticipate Earnings Update from CBAK Energy Tech

Updated Category News Views 79

Insights Into CBAK Energy Tech's Upcoming Earnings Report CBAK Energy Tech (NASDAQ: CBAT) is gearing up to unveil its quarterly earnings report, generating buzz among investors and market watchers. This report, anticipated soon, holds significant implications for the company's future outlook. Expectations for Earnings Performance Analysts are predicting an earnings per...

Continue Reading